Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian M Duchesne; Henry H Woo; Julie K Bassett; Steven J Bowe; Catherine D'Este; Mark Frydenberg; Madeleine King; Leo Ledwich; Andrew Loblaw; Shawn Malone; Jeremy Millar; Roger Milne; Rosemary G Smith; Nigel Spry; Martin Stockler; Rodney A Syme; Keen Hun Tai; Sandra Turner

Journal article

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian M Duchesne, Henry H Woo, Julie K Bassett, Steven J Bowe, Catherine D'Este, Mark Frydenberg, Madeleine King, Leo Ledwich, Andrew Loblaw, Shawn Malone, Jeremy Millar, Roger Milne, Rosemary G Smith, Nigel Spry, Martin Stockler, Rodney A Syme, Keen Hun Tai, Sandra Turner

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

DOI: 10.1016/S1470-2045(16)00107-8

University of Melbourne Researchers

Gill Duchesne Author The Sir Peter MacCallum Department of Oncology

Keen-Hun Tai Author Clinical Pathology

Roger Milne Author Melbourne School of Population and Global Health

Grants

Awarded by Australian National Health and Medical Research Council and Cancer Councils

Funding Acknowledgements

Cancer Council Victoria sponsored the trial. The trial was supported by peer-reviewed grants from the Australian National Health and Medical Research Council and Cancer Councils (number 350201), The Royal Australian and New Zealand College of Radiologists, and by an educational grant from Mayne Pharma Australia (now part of the Pfizer group). We thank the trial coordinating and contributing centres' staff, the statisticians who have previously guided the trial, and the patients who entered the study.